Neose Technologies and MacroGenics in jv
Neose Technologies and MacroGenics have entered into a research collaboration and license agreement on multiple monoclonal antibodies. Neose will apply its GlycoAdvance and GlycoPEGylation technologies to MacroGenics compounds with the goal of improving the therapeutic properties of these proteins.
Neose Technologies and MacroGenics have entered into a research collaboration and license agreement on multiple monoclonal antibodies. Neose will apply its GlycoAdvance and GlycoPEGylation technologies to MacroGenics compounds with the goal of improving the therapeutic properties of these proteins.
MacroGenics has the right to take a limited number of remodeled compounds into development.
Following the initial research phase, MacroGenics will be responsible for funding the further development of these licensed compounds under an exclusive license from Neose. In exchange, Neose will be entitled to receive various option fee, milestone, and royalty payments as products are developed and commercialised under the agreement.
'We are impressed with MacroGenics' expertise in the antibody field and look forward to working with them. They have important new technology for the development and modification of monoclonal antibodies, particularly in the Fc region, and we believe that combining our technologies may yield more effective new treatments for chronic diseases,' said C Boyd Clarke, Neose president, chief executive officer and chairman.
'We are excited by the potential therapeutic improvements that can be made to our monoclonal antibodies utilising Neose's GlycoAdvance and GlycoPEGylation technologies,' said Dr Scott Koenig, president and chief executive officer of MacroGenics.